You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.

    SBC: Acumen Pharmaceuticals, Inc            Topic: NIA

    In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC            Topic: NIA

    The United States has the highest rate of incarceration in the world There are over state and federal prisons housing over million prisoners in the United States The demographics of the prison population are shifting Longer sentences and constrained options for early release compound this trend The older adult segment of prison populations has more than tripled since The health ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Portable and Automated Radiation Effects Test Structures for Advanced Technology Nodes

    SBC: MICROELECTRONICS RESEARCH DEVELOPMENT CORPORATION            Topic: DTRA16A003

    Micro-RDC will develop portable radiation effects test structures that scales to new process nodes. These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level. The production of the chosen structures and the development of software to extract the model parameters will form the framework. A suit ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  6. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACT SUMMARY Pyruvate dehydrogenase complex PDC deficiency PDCD is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated Treatment of PDCD remains a serious unmet challenge There has never been a controlled trial of any intervention for PDCD thus there is no proven therapy for affected patients Dichloroacetate DCA ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers

    SBC: Atrin Pharmaceuticals            Topic: 103

    PROJECT SUMMARY Specific targeting of the Ataxia Telangiectasia and Rad related kinase ATR represents an emerging strategy to treat a broad spectrum of cancers most notably those that currently lack effective treatments Suppression of ATR selectively kills cells subjected to oncogenic stress alternative lengthening of telomeres ALT or loss of double strand break DSB repair mechanisms A ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Scalable, Cloud-Based Microbiome Big Data Analytics System

    SBC: WHOLE BIOME INC.            Topic: 400

    The human microbiome has emerged as a hitherto unknown causal factor in a number of disease ranging from cancer cardiovascular disease and obesity To understand the biochemical mechanisms of the human microbiome in these diseases researchers must be able to store biochemical pathway transcriptomic and metabolomic datasets in a coherent and compatible form We propose to construct a cloud ba ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Modular Pulse Charger and Laser Triggering System for Large-Scale EMP and HPM Applications

    SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC.            Topic: DTRA16A004

    For effective protection against EMP and HPM threats, it is important to understand the physics of the threats, and also to quantify the effects they have on electrical systems. EMP and HPM vulnerability testing requires delivery of high peak power and electric fields to distant targets. The most practical solution to simulate such environments is to develop a modular, optically-isolated MV-antenn ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  10. In vitro human model for individualized response to CFTR modulators

    SBC: Progenra, Inc            Topic: NHLBI

    DESCRIPTION provided by applicant The approval of the cystic fibrosis CF drug invocator for patients with the G D mutation validates CFTR modulators for improving clinical outcomes in CF For most CF patients with F del and other mutations however multi drug combination therapy will likely be necessary and sensitive biomarkers of augmented CFTR function in response to various agents ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government